0
0
For centuries, the quest for a longer life has captivated humanity, from alchemy and mythology to cutting-edge science. While the mythical philosopher’s stone remains elusive, researchers have now identified a reliable method to extend lifespan in animals: eating less. This approach, known as dietary restriction, has consistently been shown to slow aging and improve longevity by triggering beneficial biological mechanisms. However, strict dieting is challenging and unsustainable for most people, raising the question: can science offer alternatives that provide similar benefits without the hardship?
In recent years, scientists have turned their attention to pharmaceutical compounds that mimic the effects of calorie restriction. Among the most promising are rapamycin and metformin. Rapamycin, originally discovered in soil from Easter Island in the 1970s, is an immunosuppressant used to prevent organ transplant rejection. It works by inhibiting a key molecular switch (mTOR), effectively tricking cells into behaving as though nutrients are scarce—just as dietary restriction does. Metformin, a widely used diabetes medication derived from the French lilac plant, also targets nutrient-sensing pathways but has shown less consistent results in extending lifespan.
A comprehensive new study compared the impact of these drugs to that of dietary restriction. The findings were clear: dietary restriction remains the most effective way to extend lifespan, but rapamycin comes remarkably close, producing nearly equivalent benefits in several animal species and both sexes. Metformin, while safe and widely used, did not consistently prolong lifespan. Notably, combining rapamycin with another drug, trametinib, further extended the lifespan of mice.
Despite these promising results, most studies have been conducted in laboratory animals, not humans. Some research has even indicated potential risks, such as shortened lifespan in certain cases with rapamycin or excessive dietary restriction. Dr. Edward Ivimey-Cook of the University of Glasgow emphasized that while the findings do not yet justify widespread use of rapamycin, they highlight the importance of continued research into its potential for healthy aging.
The broader implications are significant. Aging is the main risk factor for most chronic diseases, including cancer, dementia, and cardiovascular disease. Even modestly slowing aging could lead to healthier, longer lives and reduce healthcare costs as populations age. Dr. Sultanova noted that drug repurposing, such as using rapamycin and metformin for longevity, is a promising strategy for enhancing both healthspan and lifespan. Both drugs are currently undergoing human clinical trials, with definitive results still awaited.
Disclaimer:
This article is intended for informational purposes only and should NOT be interpreted as medical advice. While current research on drugs like rapamycin and metformin shows potential in extending lifespan in animal models, these findings are NOT yet conclusive for humans. Always consult a qualified healthcare professional before considering any medical treatment or lifestyle change related to longevity or disease prevention1.
